Basic-Fibroblast-Growth-Factor-Mediated de novo Angiogenesis Is More Effectively Suppressed by Low-Molecular-Weight than by High-Molecular-Weight Heparin

International Journal of Microcirculation-Clinical and Experimental

Volumn 16, Issue 1, 1996, Pages 8-15

  Norrby, Klas ^a   Ostergaard P ^b  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^b NOVO NORDISK A S   (Denmark)

Author keywords

Angiogenesis; Basic fibroblast growth factor; Heparin; Molecular mass; Quantification

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ANGIOGENESIS; ANIMAL; ARTICLE; CHEMICAL PHENOMENA; COMPARATIVE STUDY; DRUG EFFECT; HUMAN; MALE; MICROCIRCULATION; RAT; SPRAGUE DAWLEY RAT; SUBCUTANEOUS DRUG ADMINISTRATION; WEIGHT GAIN;

ANIMALS; DEPRESSION, CHEMICAL; FIBROBLAST GROWTH FACTOR 2; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MICROCIRCULATION; NEOVASCULARIZATION, PHYSIOLOGIC; RATS; RATS, SPRAGUE-DAWLEY; WEIGHT GAIN;

EID: 0029719792     PISSN: 01676865     EISSN: None     Source Type: Journal    
DOI: 10.1159/000179145     Document Type: Article

References (48)

1. Norrby K: Heparin and angiogcnesis: A low-molecular-weight fraction inhibits and a high-molecular-weight fraction stimulates angiogcnesis systcmically. Haemostasis 1993;23 (suppl l):14l-149.
2. Burgess WH. Maciag T: The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem 1989:58:575-606.
3. Slavin J: Fibroblast growth factors: At the heart of angiogenesis. Cell Biol Int 1995:19:431-444.
4. Norrby K: Basic fibroblast growth factor and de novo mammalian angiogenesis. Microvasc Res 1994;48:96-113.
5. Norrby K. Jakobsson A. Sörbo J: Masl-cell-mcdiated angiogenesis: A novel experimental model using the rat mesentery. Virchows Arch 1986;52:195-202.
6. Denton J, Lewis WE, Nieduszynski LA, Phelps CF: Fractionation of heparin using antithrombin III revcrsibly bound to concanavalin A-Sepharosc. Anal Biochem 1981:118:388-391.
7. Kristcnsen HI. Tromborg EM. Nielsen JR. Nielsen JL Johansen KB. Ostcrgaard PB: Development and validation of a size exclusion chromatography method for the determination of molecular masses and molecular mass distribution in low molecular weight heparin. Thromb Res 1991:64:131-141.
8. Finney DJ: Statistical Methods in Biological Assays, ed 3. High Wycombe, Griffin. 1978.
9. Gospodarowicz D: Expression and control of vascular endothelial cells: Proliferation and differentiation by fibroblast growth factors. J Invest Dermatol 1989;93:39S-47S.
10. Rifkin DB. Moscatelli D: Recent developments in the cell biology of basic fibroblast growth factor. J Cell Biol 1989:109:1-6.
11. Norrby K: On the quantitative rat mesenteric-window assay: in Steiner R. Weisz PB, Langer R (eds): Angiogenesis: Key principles -Science - Technology - Medicine. Basel. Birkhäuser. 1992. pp 282-286.
12. Quyyumi A. Epstein SE: Letter to the Editor. J Am Coll Cardiol 1994:24:273-274.
13. Norrby K: Evidence of specificity in the action of angiogcnesis antagonists. Int J Mireocirc 1994:14:226-232.
14. Green D. Hull RD. Brant R. Pinco GF: Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin. Lancet 1992:339:1476.
15. Folkman J: What is the evidence that tumors arc angiogenesis dependent? J Natl Cancer Inst 1990:82:4-6.
16. Flaumenhaft R. Moscatelli D. Saksela O. Rifkin DB: Role of extracellular matrix in the action of basic fibroblast growth factor - Matrix as a source of growth factor for long-term stimulation of plasminogen production and DNA synthesis. J Cell Physiol 1989:140:75-81.
17. Presta M. Maicr JAM. Rusnati M. Ragnolti G: Basic fibroblast growth factor is released front endothelial extracellular matrix in a biologically active form. J Cell Physiol 1989; 140:68-74.
18. Saksela O, Moscatelli D, Sommer A, Rifkin DB: Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J Cell Biol 1988:107:743-751.
19. Moscatelli D, Rifkin DB: Membrane and matrix localization of proteascs - Common theme in tumor-cell invasion and angiogcnesis. Bio chim BiophysActa 1988;948:67-85.
20. Ishai-Michaeli R, Svahn CM, Weber M, Cha-jek-Shaul T, Komer G, Ekrc HP, Voladavskv I: Importance ofsize and sulfalation of heparin in release of basic fibroblast growth factor from the vascular endothelium and extracellular matrix. Biochemistry 1992:31:2080-2088.
21. Maccarana M. Casu B. Lindahl U: Minimal sequence in heparin/heparan sulfate required for binding of basic fibroblast growth factor. J Biol Chcm 1993:268:23898-23905.
22. Roghani M. Mansukhani A. Dcll'Era P. Bellos-la P. BasilicoC. Rifkin DB. Moscatelli D: Heparin increases the affinity of basic fibroblast growth factor for its receptor but is not required for binding. J Biol Chcm 1994:269:3976-3986.
23. Kan M, Wang F, Xu J, Crabb JW, Hou J, McKeehan WL: An essential heparin-binding domain in the fibroblast growth factor receptor kinase. Science 1993:259:1918-1920.
24. Larsen AK, Hetelekidis S, Langer R: Disposition and anticoagulant activity of biologically active heparin fragments in the rat. J Pharmacol ExpThcr 1984;231:373-378.
25. Watanabe J. Hori K. Iwamoto K. Ozeki S: Disposition of fractionated 'H-heparin in rats. J Pharmacobio Dyn 1983;6:423-432.
26. Watanabe J, Hori K, Iwamaoto K, Ozeki S: Dosc-dcpcndent disposition of fractionated H-heparin in rats. J Pharmacobiol Dyn 1985; 8:468-476.
27. Lantz M, Thysell H, Nilsson E, Olsson I: On the binding of tumor necrosis factor (TNF) to heparin and the release in vivo of the TNF-binding protein 1 by heparin. J Clin Invest 1991;88:2026-2031.
28. Klagsbrun M: Mediators of angiogencsis: The biological significance of basic fibroblast growth factor (bFGF)-heparin and heparan sulfate interactions. Cancer Biol 1992:3:81-87.
29. Park JE. Keller GA. Ferrara N: The vascular endothelial growth factor (VEGF) isoforms: Differential deposition onto the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell 1993; 4:1317-1326.
30. Witt DP, Lander AD: Differential binding of chemokines to glvcosaminoglycan subpopulations. CurrBiol 1994:4:394-400.
31. Damcron KM, Volpert OV, Tainskv MA, Bouck N: Control of angiogcnesis in fibroblasts by p53 regulation of thrombospondin-l. Science 1994:265:1582-1584.
32. O’Reilly MS, Holmgren L, Shing Y, Chen C, Rosenthal RA, Moses M, Lane WS, Cao Y, Sage EH, Folkman J: Angiostatin: A novel an-giogenesis inhibitor that mediates the suppression of métastasés by a Lewis lung carcinoma. Cell 1994;79:315-328.
33. Grainger DJ. Witchell CM. Watson JV. Metcalfe JC. Weissberg PL: Heparin decreases the rate of proliferation of rat vascular smooth muscle cells by releasing transforming growth factor ß-like activity from serum. Cardiovasc Res 1993;27:2238-2247.
34. Soker S, Svahn CM, Neufeld G: Vascular endothelial growth factor is inactivated by binding to alpha2-macroglobulin and the binding is inhibited by heparin.J Biol C'hem 1993:268: 7685-7691.
35. ls receptors. Biochem Biophys Res Commun 1994:203: 1339-1347.
36. Tesslcr S, Rockwell P, Hicklin D, Cohen T, Levi BZ, Witte L, Lcmischka IR, Neufeld G: Heparin modulates the interaction of VEGF]« with soluble and cell associated llk-l receptors. J Biol Chem 1994;269:12456-12461.
37. Vlodavsky I. Ishai-Michaeli R. Mohsen M. Bar-Shavit R. Catane R. Ekre HPT, Svahn CM: Modulation of neovascularization and metastasis by species of heparin; in Lane DA. Björk I. Lindahl U (eds); Heparin and Related Polysaccharides. New York. Plenum. 1992. pp 317-327.
38. Tina YP, Montgomery KF, Clowes AW: Heparin inhibits collagcnase gene expression mediated by phorbol ester-responsive elements in primate arterial smooth muscle cells. Circ Res 1992;70:1062-1069.
39. Hopwood JJ: Enzymes that degrade heparin and heparan sulphate; in Lane DA, Lindahl U (eds): Heparin: Chemical and Biological Properties - Clinical Application. London. Arnold. 1989. pp 191-227.
40. Hahnenberger R, Jakobson AM, Ansari A, Wehler T, Svahn CM, Lindahl U: Low-sul-phatcd oligosaccharides derived from heparan sulphate inhibit normal angiogencsis. Glyco-biology 1993;3:567-573.
41. Norrby K. Sorbo J: Heparin enhances angiogcnesis by a systemic mode of action. Int J Exp Pathol 1992:73:147-155.
42. Maione TE, Gray GS, Petro J, Hunt AJ, Don-ner AL, Bauer SI, Carson HF, Sharpe RJ: Inhibition of angiogencsis by recombinant human platelet factor-4 and related peptides. Science 1990:247:77-79.
43. McCaffrey TA. Falcone DJ. Du B: Transforming growth factor-pl is a heparin-binding protein. Identification of putative heparin-binding regions and isolation of heparins with vary ing affinity for TGF-pi. J Cell Physiol 1992:152: 430-440.
44. Novotny WF, Mafifi T, Mehta RL, Milner PG: Identification of novel heparin-rclcasablc proteins. as well as the cytokines ntidkine and pleiotrophin, in human postheparin plasma. Artcriosclcr Thromb 1993; 13:1798-1805.
45. Belford DA, Hendry IA, Parish CR: Ability of different chemically modified heparins to potentiate the biological activity of heparin-binding growth factor 1: Lack of correlation with growth factor binding. Biochemistry 1992:31: 6498-6503.
46. Norrby K. Jakobsson A. Sorbo J: Age-dependent mast-cell-mediated angiogcnesis. APMIS 1988:96(suppl 2):251-26l.
47. Hansen-Smith FM. Joswiak GJ. Baustert JL: Regional differences in spontaneously occurring angiogencsis in the adult rat mesentery. Microvasc Res 1994:47:369-376.
48. Jakobsson AE: Angiogencsis induced by mast cell secretion in rat peritoneal connective tissue is a process of three phases. Microvasc Res 1994:47:252-269.